Patents by Inventor Hien Thuy Zhao
Hien Thuy Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959080Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.Type: GrantFiled: October 4, 2021Date of Patent: April 16, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
-
Publication number: 20230374519Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PMP22 RNA in a cell or animal, and in certain instances reducing the amount of PMP22 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include demyelination, progressive axonal damage and/or loss, weakness and wasting of foot and lower leg muscles, foot deformities, and weakness and atrophy in the hands. Such neurodegenerative diseases include Charcot-Marie-Tooth disease.Type: ApplicationFiled: June 18, 2021Publication date: November 23, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Holly Kordasiewicz, Punit P. Seth, Hien Thuy Zhao, Michael T. Migawa, Ruben E. Valas, Thazha P. Prakash
-
Publication number: 20230357770Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APOE RNA in a cell or animal, and in certain instances reducing the amount of APOE protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include cognitive impairment, progressive memory loss, behavioral abnormality, dementia, difficulty performing daily activities, amyloid plaques, neurofibrillary tangles, and neuroinflammation.Type: ApplicationFiled: September 23, 2021Publication date: November 9, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tracy A. Cole, Swagatam Mukhopadhyay, Huynh-Hoa Bui, Priyam Singh, Holly Kordasiewicz, Susan M. Freier, Hien Thuy Zhao
-
Publication number: 20230055405Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or animal, and in certain instances reducing the amount of APP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease or disorder. Such symptoms and hallmarks include cognitive impairment, including a decline in memory and language skills, behavioral and psychological symptoms such as apathy and lack of motivation, gait disturbances and seizures, progressive dementia, and abnormal amyloid deposits.Type: ApplicationFiled: July 28, 2021Publication date: February 23, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Huynh-Hoa Bui, Susan M. Freier, Hien Thuy Zhao, Holly Kordasiewicz, Ruben E. Valas, Thazha P. Prakash, W. Brad Wan
-
Patent number: 11530411Abstract: Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.Type: GrantFiled: December 17, 2020Date of Patent: December 20, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Holly Kordasiewicz
-
Publication number: 20220251553Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.Type: ApplicationFiled: October 4, 2021Publication date: August 11, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
-
Publication number: 20220195431Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).Type: ApplicationFiled: February 21, 2020Publication date: June 23, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Holly Kordasiewicz, Ruben E. Valas
-
Publication number: 20220112503Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PMP22 RNA in a cell or animal, and in certain instances reducing the amount of PMP22 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include demyelination, progressive axonal damage and/or loss, weakness and wasting of foot and lower leg muscles, foot deformities, and weakness and atrophy in the hands. Such neurodegenerative diseases include Charcot-Marie-Tooth disease.Type: ApplicationFiled: December 20, 2019Publication date: April 14, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Huynh-Hoa Bui, Susan M. Freier, Hien Thuy Zhao, Priyam Singh
-
Publication number: 20220025366Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or animal, and in certain instances reducing the amount of PrP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks spongiform changes in the brain, development of abnormal protein aggregates, neuronal loss, markers of neuronal loss, rapidly progressing dementia, and death. Such neurodegenerative diseases include prion diseases, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), familial Creutzfeldt-Jakob Disease (fCJD), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, kuru, Alzheimer's disease, or Parkinson's disease.Type: ApplicationFiled: November 21, 2019Publication date: January 27, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Huynh-Hoa Bui, Hien Thuy Zhao
-
Publication number: 20210340546Abstract: Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.Type: ApplicationFiled: December 17, 2020Publication date: November 4, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Holly Kordasiewicz
-
Patent number: 11136577Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.Type: GrantFiled: March 9, 2017Date of Patent: October 5, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
-
Patent number: 10907160Abstract: Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.Type: GrantFiled: January 5, 2017Date of Patent: February 2, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Holly Kordasiewicz
-
Publication number: 20190062741Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.Type: ApplicationFiled: March 9, 2017Publication date: February 28, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
-
Publication number: 20180362988Abstract: Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.Type: ApplicationFiled: January 5, 2017Publication date: December 20, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Hien Thuy Zhao, Holly Kordasiewicz